The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
deepDR: a network-based deep learning approach to in silico drug repositioning
Open accessAbstract
Motivation: Traditional drug discovery and development are often time-consuming and high risk. Repurposing/repositioning of approved drugs offers a relatively low-cost and high-efficiency approach toward rapid development of efficacious treatments. The emergence of large-scale, heterogeneous biological networks has offered unprecedented opportunities for developing in silico drug repositioning approaches. However, capturing highly non-linear, heterogeneous network structures by most existing approaches for drug repositioning has been challenging. Results: In this study, we developed a network-based deep-learning approach, termed deepDR, for in silico drug repurposing by integrating 10 networks: one drug–disease, one drug-side-effect, one drug–target and seven drug–drug networks. Specifically, deepDR learns high-level features of drugs from the heterogeneous networks by a multi-modal deep autoencoder. Then the learned low-dimensional representation of drugs together with clinically reported drug–disease pairs are encoded and decoded collectively via a variational autoencoder to infer candidates for approved drugs for which they were not originally approved. We found that deepDR revealed high performance [the area under receiver operating characteristic curve (AUROC) = 0.908], outperforming conventional network-based or machine learning-based approaches. Importantly, deepDR-predicted drug–disease associations were validated by the ClinicalTrials.gov database (AUROC = 0.826) and we showcased several novel deepDR-predicted approved drugs for Alzheimer’s disease (e.g. risperidone and aripiprazole) and Parkinson’s disease (e.g. methylphenidate and pergolide). Availability and implementation: Source code and data can be downloaded from https://github.com/ChengF-Lab/deepDR Supplementary information: Supplementary data are available online at Bioinformatics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Cortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
(2008) · Journal of Machine Learning Research · Cited by 33,051
High-performance medicine: the convergence of human and artificial intelligence
Topol, E. J. (2019) · Nature Medicine · doi:10.1038/s41591-018-0300-7 · Cited by 10,450
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
(2010) · Journal of Machine Learning Research · doi:10.5555/1756006.1953039 · Cited by 4,051
Opportunities and obstacles for deep learning in biology and medicine
Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., Ferrero, E., Agapow, P.-M., Zietz, M., Hoffman, M. M., et al. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0387 · Cited by 2,310
DrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993
Self-citationDeep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473
Walking the Interactome for Prioritization of Candidate Disease Genes
Köhler, S., Bauer, S., Horn, D., & Robinson, P. N. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.02.013 · Cited by 1,258
Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L., & Zeng, J. (2017) · Nature Communications · doi:10.1038/s41467-017-00680-8 · Cited by 916
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
Self-citationExtracting semantic representations from word co-occurrence statistics: A computational study
Bullinaria, J. A., & Levy, J. P. (2007) · Behavior Research Methods · doi:10.3758/bf03193020 · Cited by 805
Network-based prediction of drug combinations
Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019) · Nature Communications · doi:10.1038/s41467-019-09186-x · Cited by 800
Self-citationNetwork-based approach to prediction and population-based validation of in silico drug repurposing
Cheng, F., Desai, R. J., Handy, D. E., Wang, R., Schneeweiss, S., Barabási, A.-L., & Loscalzo, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05116-5 · Cited by 552
Self-citationTreatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
The $2.6 Billion Pill — Methodologic and Policy Considerations
Avorn, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500848 · Cited by 318
Inductive matrix completion for predicting gene–disease associations
Natarajan, N., & Dhillon, I. S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu269 · Cited by 311
A standard database for drug repositioning
Brown, A. S., & Patel, C. J. (2017) · Scientific Data · doi:10.1038/sdata.2017.29 · Cited by 305
Li, J., Zhu, M., Manning-Bog, A. B., Di Monte, D. A., & Fink, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0770fje · Cited by 258
deepNF: deep network fusion for protein function prediction
Gligorijević, V., Barot, M., & Bonneau, R. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty440 · Cited by 236
Greene, J. A., & Loscalzo, J. (2017) · New England Journal of Medicine · doi:10.1056/nejmms1706744 · Cited by 205
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease
Deyn, P. P. D., Jeste, D. V., Swanink, R., Kostic, D., Breder, C. D., Carson, W. H., & Iwamoto, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178415.22309.8f · Cited by 150
Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
Mendonça, D. A., Menezes, K., & Jog, M. (2007) · Movement Disorders · doi:10.1002/mds.21656 · Cited by 150
Singh-Blom, U. M., Natarajan, N., Tewari, A., Woods, J. O., Dhillon, I. S., & Marcotte, E. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058977 · Cited by 145
Cao, M., Pietras, C. M., Feng, X., Doroschak, K. J., Schaffner, T., Park, J., Zhang, H., Cowen, L., & Hescott, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu263 · Cited by 120
Katz, I., de Deyn, P., Mintzer, J., Greenspan, A., Zhu, Y., & Brodaty, H. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1792 · Cited by 110
Ohm, T. G., Böhl, J., & Lemmer, B. (1991) · Brain Research · doi:10.1016/0006-8993(91)90512-t · Cited by 93
Cheng, F., Hong, H., Yang, S., & Wei, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw051 · Cited by 90
Self-citationAripiprazole in the treatment of Alzheimer's disease
Deyn, P. P. D., Drenth, A. F. J., Kremer, B. P. H., Voshaar, R. C. O., & Dam, D. V. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.764989 · Cited by 63
Devos, D., Moreau, C., Delval, A., Dujardin, K., Defebvre, L., & Bordet, R. (2012) · CNS Drugs · doi:10.1007/s40263-012-0017-y · Cited by 47
Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders
Auriel, E., Hausdorff, J. M., & Giladi, N. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318170576c · Cited by 41
Paul Ehrlich (1854-1915): man with the magic bullet.
Tan, S. Y., & Grimes, S. (2010) · PubMed · Cited by 35
Loss of β-adrenoceptor response in myocytes overexpressing the Na+/Ca2+-exchanger
Sato, M. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.09.010 · Cited by 34
Storch, A., Trenkwalder, C., Oehlwein, C., Winkelmann, J., Polzer, U., Hundemer, H., & Schwarz, J. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.03.005 · Cited by 18
Cited by
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Self-citationArtificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“The results concluded that deepDR predicted approved drugs such as risperidone and aripiprazole for the treatment of Alzheimer’s disease (AD), whereas methylphenidate and pergolide for treatment of Parkinson’s disease (PD) [291].”
BackgroundMethodDeep learning in cancer diagnosis, prognosis and treatment selection
Tran, K. A., Kondrashova, O., Bradley, A., Williams, E. D., Pearson, J. V., & Waddell, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-00968-x · Cited by 932
Artificial Intelligence in Cancer Research and Precision Medicine
Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0090 · Cited by 781
Multimodal deep learning for biomedical data fusion: a review
Stahlschmidt, S. R., Ulfenborg, B., & Synnergren, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab569 · Cited by 766
Metadata
- Authors
- Zeng, X., Zhu, S., Liu, X., Zhou, Y., Nussinov, R., & Cheng, F.
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-22
- Volume
- 35
- Issue
- 24
- Pages
- 5191-5198
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- OpenAlex
- W2946099214
- Cited by
- 535
- References
- 37
- FWCI
- 43.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.